Literature DB >> 15890952

Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry.

Andre J Marozsan1, Dawn M Moore, Michael A Lobritz, Erika Fraundorf, Awet Abraha, Jacqueline D Reeves, Eric J Arts.   

Abstract

The ability of one primary human immunodeficiency virus type 1 (HIV-1) isolate to outcompete another in primary CD4+ human lymphoid cells appears to be mediated by the efficiency of host cell entry. This study was designed to test the role of entry on fitness of wild-type HIV-1 isolates (e.g., replicative capacity) and to examine the mechanism(s) involved in differential entry efficiency. The gp120 coding regions of two diverse HIV-1 isolates (the more-fit subtype B strain, B5-91US056, and less-fit C strain, C5-97ZA003) were cloned into a neutral HIV-1 backbone by using a recently described yeast cloning technique. The fitness of the primary B5 HIV-1 isolates and its env gene cloned into the NL4-3 laboratory strain had similar fitness, and both were more fit than the C5 primary isolate and its env/NL4-3 chimeric counterpart. Increased fitness of the B5 over C5 virus was mediated by the gp120 coding region of the env gene. An increase in binding/fusion, as well as decreased sensitivity to entry inhibitors (PSC-RANTES and T-20), was observed in cell fusion assays mediated by B5 gp120 compared to C5 gp120. Competitive binding assays using a novel whole virus-cell system indicate that the primary or chimeric B5 had a higher avidity for CD4/CCR5 on host cells than the C5 counterpart. This increased avidity of an HIV-1 isolate for its cell receptors may be a significant factor influencing overall replicative capacity or fitness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890952      PMCID: PMC1112120          DOI: 10.1128/JVI.79.11.7121-7134.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

2.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

3.  Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates.

Authors:  Andre J Marozsan; Eric J Arts
Journal:  J Virol Methods       Date:  2003-08       Impact factor: 2.014

4.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 envelope-mediated neuronal death: uncoupling of viral replication and neurotoxicity.

Authors:  Kunyan Zhang; Farazana Rana; Claudia Silva; Julie Ethier; Kathy Wehrly; Bruce Chesebro; Christopher Power
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.

Authors:  Jason D Barbour; Terri Wrin; Robert M Grant; Jeffrey N Martin; Mark R Segal; Christos J Petropoulos; Steven G Deeks
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Construction and characterisation of a full-length infectious molecular clone from a fast replicating, X4-tropic HIV-1 CRF02.AG primary isolate.

Authors:  Denis M Tebit; Léopold Zekeng; Lazare Kaptué; Hans-Georg Kräusslich; Ottmar Herchenröder
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

8.  Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.

Authors:  Béatrice Labrosse; Jean-Louis Labernardière; Elisabeth Dam; Virginie Trouplin; Katharina Skrabal; François Clavel; Fabrizio Mammano
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C.

Authors:  Sarah C Ball; Awet Abraha; Kalonji R Collins; Andre J Marozsan; Heather Baird; Miguel E Quiñones-Mateu; Adam Penn-Nicholson; Michael Murray; Nathalie Richard; Michael Lobritz; Peter A Zimmerman; Tatsuyoshi Kawamura; Andrew Blauvelt; Eric J Arts
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.

Authors:  N Sullivan; Y Sun; Q Sattentau; M Thali; D Wu; G Denisova; J Gershoni; J Robinson; J Moore; J Sodroski
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

View more
  51 in total

1.  Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.

Authors:  Jaclyn K Wright; Vladimir Novitsky; Mark A Brockman; Zabrina L Brumme; Chanson J Brumme; Jonathan M Carlson; David Heckerman; Bingxia Wang; Elena Losina; Mopo Leshwedi; Mary van der Stok; Lungile Maphumulo; Nompumelelo Mkhwanazi; Fundisiwe Chonco; Philip J R Goulder; Max Essex; Bruce D Walker; Thumbi Ndung'u
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.

Authors:  Philippe Selhorst; Carina Combrinck; Nonkululeko Ndabambi; Sherazaan D Ismail; Melissa-Rose Abrahams; Miguel Lacerda; Natasha Samsunder; Nigel Garrett; Quarraisha Abdool Karim; Salim S Abdool Karim; Carolyn Williamson
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.

Authors:  Wuwei Wu; Derek C Blythe; Hyelee Loyd; Robert H Mealey; Rebecca L Tallmadge; Karin S Dorman; Susan Carpenter
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 4.  The high cost of fidelity.

Authors:  Sarah B Lloyd; Stephen J Kent; Wendy R Winnall
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01       Impact factor: 2.205

5.  Short Communication: A Recombinant Variant with Increased Envelope Entry Efficiency Emerged During Early Infection of an HIV-1 Subtype C Dual Infected Rapid Progressor.

Authors:  Kerry Gordon; Shatha Omar; Andile Nofemela; Gama Bandawe; Carolyn Williamson; Zenda Woodman
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-20       Impact factor: 2.205

6.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

7.  Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.

Authors:  Marion W Kiguoya; Jaclyn K Mann; Denis Chopera; Kamini Gounder; Guinevere Q Lee; Peter W Hunt; Jeffrey N Martin; T Blake Ball; Joshua Kimani; Zabrina L Brumme; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

8.  Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Authors:  Michael A Lobritz; Annette N Ratcliff; Andre J Marozsan; Dawn M Dudley; John C Tilton; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

9.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.

Authors:  Behzad Etemad; Angela Fellows; Brenda Kwambana; Anupa Kamat; Yang Feng; Sandra Lee; Manish Sagar
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.